According to the latest global cancer statistics,colorectal cancer(CRC)is the most common malignancy of the digestive system and the second most lethal among all cancer types(1).In China,CRC is the second most prevale...According to the latest global cancer statistics,colorectal cancer(CRC)is the most common malignancy of the digestive system and the second most lethal among all cancer types(1).In China,CRC is the second most prevalent cancer,following only after lung cancer(2).The first version of the Chinese Society of Clinical Oncology(CSCO)guideline was launched in 2017 and has been updated annually based on the latest findings of clinical research,drug accessibility and expert consensus(3-8).Here,we present the main updates of the 2024 version compared to the 2023 version.展开更多
Colorectal cancer(CRC)is the second most common cancer and the most common type of gastrointestinal cancer with rapidly increasing incidence and mortality in China(1,2).Since the first edition of the Chinese Society o...Colorectal cancer(CRC)is the second most common cancer and the most common type of gastrointestinal cancer with rapidly increasing incidence and mortality in China(1,2).Since the first edition of the Chinese Society of Clinical Oncology(CSCO)guideline was published in2017,the guideline has been updated annually according to the latest results of clinical research at home and abroad,the accessibility of drugs and the opinions of CSCO experts(3-7).展开更多
Colorectal cancer(CRC)is the second most common cancer in China,the morbidity and mortality rates of which are rapidly increasing1,2.Among newly-diagnosed CRC patients,20%have metastatic disease at the time of present...Colorectal cancer(CRC)is the second most common cancer in China,the morbidity and mortality rates of which are rapidly increasing1,2.Among newly-diagnosed CRC patients,20%have metastatic disease at the time of presentation and an additional 25%present with localized disease and will subsequently develop metastases3.The treatment of metastatic colorectal cancer(mCRC)is gradually moving towards the era of precision therapy,which involves guided treatment based on individual genetic characteristics4.Since the first edition of the Chinese Society of Clinical Oncology(CSCO)guidelines was published in 2017,the guidelines have been updated annually according to the latest clinical trial findings5-9.Herein we summarize how the CSCO guidelines enable tailor-made treatments of mCRC with different molecular characteristics(Figure 1).展开更多
2021年4月,中国临床肿瘤学会(Chinese Society of Clinical Oncology,CSCO)乳腺癌专家委员会发布了2021年的CSCO《乳腺癌诊疗指南》。新版指南在2020年指南的基础上,秉承循证医学证据、兼顾诊治方案可及性的原则,对乳腺癌的诊断检查、...2021年4月,中国临床肿瘤学会(Chinese Society of Clinical Oncology,CSCO)乳腺癌专家委员会发布了2021年的CSCO《乳腺癌诊疗指南》。新版指南在2020年指南的基础上,秉承循证医学证据、兼顾诊治方案可及性的原则,对乳腺癌的诊断检查、治疗评估等内容做了推荐调整,同时新增了“靶向药物不良反应管理”、“常态化疫情防控下乳腺癌患者管理”等章节,以期更好地实现患者的全程管理。该文总结新版指南更新要点,并结合最新循证医学进展和药物可及性变化进行了解读。展开更多
对于晚期或转移性胃癌患者,目前公认采取以全身抗肿瘤药物治疗为主的多学科综合治疗和全程多方位管理以延长患者生存时间和改善患者生存质量。中国临床肿瘤学会(CSCO)胃癌诊疗指南每年更新,融合国内外最新的临床研究进展,关注中国人群...对于晚期或转移性胃癌患者,目前公认采取以全身抗肿瘤药物治疗为主的多学科综合治疗和全程多方位管理以延长患者生存时间和改善患者生存质量。中国临床肿瘤学会(CSCO)胃癌诊疗指南每年更新,融合国内外最新的临床研究进展,关注中国人群研究数据和贴近本国临床实践。2021版CSCO转移性胃癌诊疗指南更新主要围绕免疫治疗、抗HER2靶向治疗和胃癌支持治疗等方面展开。基于2020年晚期胃癌在免疫治疗取得重大突破,更新重点聚焦免疫治疗,2021版CSCO指南从新的临床证据出发,针对免疫治疗从一线到三线,如何选择不同的程序性死亡受体-1(programmed cell death 1,PD-1)单抗药物,不同的适用人群均作出了详细推荐及注释,以期规范免疫治疗在晚期胃癌中的应用。本文就2021版CSCO指南对免疫治疗、抗HER2靶向治疗和胃癌支持治疗等方面的更新作总结性的解读,概括性阐明2021版CSCO中反映的晚期转移性胃癌治疗的新进展。展开更多
非小细胞肺癌是肺癌最常见的病理类型。近年来随着医学技术的发展,包括靶向治疗和免疫治疗在内的新的治疗手段改善了非小细胞肺癌患者的预后。中国临床肿瘤学会(Chinese Society of Clinical Oncology,CSCO)每年结合最新的研究进展更新...非小细胞肺癌是肺癌最常见的病理类型。近年来随着医学技术的发展,包括靶向治疗和免疫治疗在内的新的治疗手段改善了非小细胞肺癌患者的预后。中国临床肿瘤学会(Chinese Society of Clinical Oncology,CSCO)每年结合最新的研究进展更新《CSCO非小细胞肺癌诊疗指南》。该指南系统介绍非小细胞肺癌的诊疗规范,为临床诊疗工作安全规范的开展提供理论依据。本文结合2021年CSCO指南更新要点进行详细解读,以期为非小细胞肺癌1年来的治疗进展要点内容带来更深层次的理解。展开更多
Colorectal cancer(CRC) is one of the major cancers threatening life and health of Chinese residents. According to the latest data released by the National Cancer Center in2015(1), there were 387,000 new cases and 187,...Colorectal cancer(CRC) is one of the major cancers threatening life and health of Chinese residents. According to the latest data released by the National Cancer Center in2015(1), there were 387,000 new cases and 187,100 deaths of CRC in China, accounting for 9.87% and 8.01% of all malignancies. The first version of the Chinese Society of Clinical Oncology(CSCO) guidelines was released in April2017, and has been updated annually based on the latest clinical research data and the availability of new drugs(2-4). Here, we present the main updates of the 2021 version compared to 2020 version.展开更多
In April 2017,the first edition Chinese Society of Clinical Oncology Breast Cancer(CSCO BC)guidelines were released.These guidelines were based on medical evidence,as well as the accessibility and cost effectiveness o...In April 2017,the first edition Chinese Society of Clinical Oncology Breast Cancer(CSCO BC)guidelines were released.These guidelines were based on medical evidence,as well as the accessibility and cost effectiveness of various anticancer drugs in China.The CSCO BC guidelines include regimens with a high level of evidence,good product accessibility and high consistent consensus among Chinese experts as level I recommendations.Regimens with a high level of evidence but poor product accessibility or expert consensus are included as level II recommendations.展开更多
基金supported by the Provincial Key R&D Program of Zhejiang Province(No.2021C03125)National Natural Science Foundation of China(No.82373415 and No.82302489)Beijing Xisike Clinical Oncology Research Foundation(No.Y-tongshu2021/ms-0003).
文摘According to the latest global cancer statistics,colorectal cancer(CRC)is the most common malignancy of the digestive system and the second most lethal among all cancer types(1).In China,CRC is the second most prevalent cancer,following only after lung cancer(2).The first version of the Chinese Society of Clinical Oncology(CSCO)guideline was launched in 2017 and has been updated annually based on the latest findings of clinical research,drug accessibility and expert consensus(3-8).Here,we present the main updates of the 2024 version compared to the 2023 version.
基金supported by the Provincial Key R&D Program of Zhejiang Province(No.2021C03125)Beijing Xisike Clinical Oncology Research Foundation(No.Y-tongshu2021/ms-0003)。
文摘Colorectal cancer(CRC)is the second most common cancer and the most common type of gastrointestinal cancer with rapidly increasing incidence and mortality in China(1,2).Since the first edition of the Chinese Society of Clinical Oncology(CSCO)guideline was published in2017,the guideline has been updated annually according to the latest results of clinical research at home and abroad,the accessibility of drugs and the opinions of CSCO experts(3-7).
基金supported by the Provincial Key R&D Program of Zhejiang Province(Grant No.2021C03125)the Beijing Xisike Clinical Oncology Research Foundation(Grant No.Y-tongshu2021/ms-0003).
文摘Colorectal cancer(CRC)is the second most common cancer in China,the morbidity and mortality rates of which are rapidly increasing1,2.Among newly-diagnosed CRC patients,20%have metastatic disease at the time of presentation and an additional 25%present with localized disease and will subsequently develop metastases3.The treatment of metastatic colorectal cancer(mCRC)is gradually moving towards the era of precision therapy,which involves guided treatment based on individual genetic characteristics4.Since the first edition of the Chinese Society of Clinical Oncology(CSCO)guidelines was published in 2017,the guidelines have been updated annually according to the latest clinical trial findings5-9.Herein we summarize how the CSCO guidelines enable tailor-made treatments of mCRC with different molecular characteristics(Figure 1).
文摘2021年4月,中国临床肿瘤学会(Chinese Society of Clinical Oncology,CSCO)乳腺癌专家委员会发布了2021年的CSCO《乳腺癌诊疗指南》。新版指南在2020年指南的基础上,秉承循证医学证据、兼顾诊治方案可及性的原则,对乳腺癌的诊断检查、治疗评估等内容做了推荐调整,同时新增了“靶向药物不良反应管理”、“常态化疫情防控下乳腺癌患者管理”等章节,以期更好地实现患者的全程管理。该文总结新版指南更新要点,并结合最新循证医学进展和药物可及性变化进行了解读。
文摘对于晚期或转移性胃癌患者,目前公认采取以全身抗肿瘤药物治疗为主的多学科综合治疗和全程多方位管理以延长患者生存时间和改善患者生存质量。中国临床肿瘤学会(CSCO)胃癌诊疗指南每年更新,融合国内外最新的临床研究进展,关注中国人群研究数据和贴近本国临床实践。2021版CSCO转移性胃癌诊疗指南更新主要围绕免疫治疗、抗HER2靶向治疗和胃癌支持治疗等方面展开。基于2020年晚期胃癌在免疫治疗取得重大突破,更新重点聚焦免疫治疗,2021版CSCO指南从新的临床证据出发,针对免疫治疗从一线到三线,如何选择不同的程序性死亡受体-1(programmed cell death 1,PD-1)单抗药物,不同的适用人群均作出了详细推荐及注释,以期规范免疫治疗在晚期胃癌中的应用。本文就2021版CSCO指南对免疫治疗、抗HER2靶向治疗和胃癌支持治疗等方面的更新作总结性的解读,概括性阐明2021版CSCO中反映的晚期转移性胃癌治疗的新进展。
文摘非小细胞肺癌是肺癌最常见的病理类型。近年来随着医学技术的发展,包括靶向治疗和免疫治疗在内的新的治疗手段改善了非小细胞肺癌患者的预后。中国临床肿瘤学会(Chinese Society of Clinical Oncology,CSCO)每年结合最新的研究进展更新《CSCO非小细胞肺癌诊疗指南》。该指南系统介绍非小细胞肺癌的诊疗规范,为临床诊疗工作安全规范的开展提供理论依据。本文结合2021年CSCO指南更新要点进行详细解读,以期为非小细胞肺癌1年来的治疗进展要点内容带来更深层次的理解。
基金supported by the National Key R&D Program of China (No. 2018YFC1312100)the National Natural Science Foundation of China (No. 81872481)Traditional Chinese Medicine (Integrated Chinese and Western Medicine) Key Discipline Construction Project of Zhejiang Province (No. 2017-XK-A40)。
文摘Colorectal cancer(CRC) is one of the major cancers threatening life and health of Chinese residents. According to the latest data released by the National Cancer Center in2015(1), there were 387,000 new cases and 187,100 deaths of CRC in China, accounting for 9.87% and 8.01% of all malignancies. The first version of the Chinese Society of Clinical Oncology(CSCO) guidelines was released in April2017, and has been updated annually based on the latest clinical research data and the availability of new drugs(2-4). Here, we present the main updates of the 2021 version compared to 2020 version.
基金This work was supported by the Capital Clinical Characteristic Application Research(Grant No.Z181100001718215)the innovative projects of PLA General Hospital(Grant No.CX19011).
文摘In April 2017,the first edition Chinese Society of Clinical Oncology Breast Cancer(CSCO BC)guidelines were released.These guidelines were based on medical evidence,as well as the accessibility and cost effectiveness of various anticancer drugs in China.The CSCO BC guidelines include regimens with a high level of evidence,good product accessibility and high consistent consensus among Chinese experts as level I recommendations.Regimens with a high level of evidence but poor product accessibility or expert consensus are included as level II recommendations.